beta

VCYT

Veracyte Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Market Cap: 1.63 Billion

Primary Exchange: NASDAQ

Website: https://www.veracyte.com/

Shares Outstanding: 73 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 2.199455897860695

Sector: Health Care and Social Assistance

Industry: Medical Laboratories

Ethical Flags

Longest drawdown: 1263 trading days

From: 2014-03-19 To: 2019-01-31

Lowest Point:

Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

via: Business Wire at 2019-06-10 12:15:00:000

Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the companys Afirma Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer d… read more...

Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

via: Business Wire at 2019-06-10 12:15:00:000

Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the companys Afirma Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer d… read more...

Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

via: Business Wire at 2019-06-10 12:15:00:000

Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the companys Afirma Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer d… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud